Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Up 61.6% in September

Key Points

• Gain Therapeutics saw a significant increase in short interest, up 61.6% in September, bringing the total to 377,100 shares.
• Analysts maintain a mixed outlook on the stock with ratings ranging from a "sell" to several "buy" ratings, and a consensus price target of $8.00.
• Gain Therapeutics reported a quarterly loss of ($0.19) per share, missing analyst expectations, as it focuses on developing small molecule therapeutics.

Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) was the target of a large growth in short interest during the month of September. As of September 15th, there was short interest totaling 377,100 shares, a growth of 61.6% from the August 31st total of 233,300 shares. Approximately 1.1% of the company's stock are sold short. Based on an average daily trading volume, of 430,300 shares, the days-to-cover ratio is presently 0.9 days. Based on an average daily trading volume, of 430,300 shares, the days-to-cover ratio is presently 0.9 days. Approximately 1.1% of the company's stock are sold short.

Wall Street Analyst Weigh In

A number of research firms recently commented on GANX. Weiss Ratings reissued a "sell (e+)" rating on shares of Gain Therapeutics in a report on Saturday, September 27th. BTIG Research reiterated a "buy" rating and set a $9.00 target price on shares of Gain Therapeutics in a report on Monday, September 8th. Roth Capital cut their price target on Gain Therapeutics from $7.00 to $6.00 and set a "buy" rating on the stock in a research note on Wednesday, August 13th. Finally, HC Wainwright reiterated a "buy" rating and issued a $8.00 price target on shares of Gain Therapeutics in a research note on Thursday, July 3rd. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $8.00.

Gain Therapeutics Trading Up 3.2%

Shares of NASDAQ:GANX opened at $1.92 on Monday. The company has a current ratio of 1.79, a quick ratio of 1.79 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $69.02 million, a PE ratio of -3.05 and a beta of 0.11. Gain Therapeutics has a 1 year low of $1.41 and a 1 year high of $3.19. The firm has a fifty day moving average price of $1.71 and a 200 day moving average price of $1.79.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.02). Analysts expect that Gain Therapeutics will post -1 EPS for the current fiscal year.

Hedge Funds Weigh In On Gain Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its position in Gain Therapeutics by 2.9% in the second quarter. Geode Capital Management LLC now owns 290,462 shares of the company's stock worth $523,000 after purchasing an additional 8,251 shares in the last quarter. Marshall Wace LLP lifted its holdings in Gain Therapeutics by 41.0% in the second quarter. Marshall Wace LLP now owns 276,433 shares of the company's stock valued at $498,000 after buying an additional 80,407 shares during the period. Dauntless Investment Group LLC acquired a new stake in shares of Gain Therapeutics during the first quarter worth $240,000. Finally, Kovitz Investment Group Partners LLC bought a new position in shares of Gain Therapeutics during the 1st quarter valued at about $91,000. Institutional investors and hedge funds own 11.97% of the company's stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.